Invenshure

Invenshure originates intellectual property internally or in close partnership with research institutions rather than evaluating third-party pitch decks as its primary sourcing channel. The firm often co-invents the foundational technology, recruits management, and leads the earliest capital formation, retaining significant ownership and board influence through clinical or commercial proof points. This makes Invenshure more comparable to a venture studio or an internal corporate R&D function than a standard LP-backed fund.

Both institutions represent consistent sources of proprietary deal flow for the firm. Invenshure has structured multiple companies around technology licensed from the Mayo Clinic and the University of Minnesota, leveraging Minneapolis’s strong academic-medical research corridor. The specific licensing and revenue-share terms are negotiated on a per-company basis and are not publicly disclosed.

Co-founders Danny Cunagin (Managing Partner) and Troy Kopischke (Partner) lead the firm’s investment and company-building decisions. Cunagin’s background includes prior operating and venture roles in medical technology, while Kopischke brings experience in venture formation and deal structuring. The firm does not maintain a large investment committee; decisions are made by the partners alongside domain-specific scientific advisors on a case-by-case basis.

Invenshure is not a single-family office. It operates as an asset manager with a venture capital fund structure that raises capital from external institutional and high-net-worth limited partners alongside its internal commitments. The exact LP composition and fund sizes have not been publicly disclosed.

Invenshure concentrates heavily on formation-stage and pre-seed investments, often writing the first institutional check. It typically maintains a reserve for follow-on participation in subsequent financing rounds, particularly through Series A and B, especially when the initial thesis de-risks through regulatory or clinical milestones. The firm does not position itself as a late-stage or crossover investor.